Showing 4181-4190 of 5771 results for "".
- Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021https://modernod.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/Johnson & Johnson Vision will present nearly 30 posters and papers of research data on myopia, IOL, phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meet
- Ocular Therapeutix to Present Preclinical and Clinical Data at ARVOhttps://modernod.com/news/ocular-therapeutix-to-present-preclinical-and-clinical-data-at-arvo/2479146/Ocular Therapeutix announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. With the ARVO 2021 Annual Meeting being moved to a virtual format, video-recorded presentations are scheduled to become available online at ARVOLearn o
- Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLighthttps://modernod.com/news/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/2479143/Lumenis announced that the FDA has granted De Novo authorization for Lumenis’ newest intense pulsed light (IPL) device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). The Lumenis multicenter, double-blinded, randomized controlled FDA trial showed that
- Alcon to Acquire US Commercialization Rights to Glaucoma Eye Drop Simbrinzahttps://modernod.com/news/alcon-to-acquire-us-commercialization-rights-to-ophthalmic-eye-drop-simbrinza/2479138/Alcon announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Under terms of the deal, Alcon will pay $355 million at closing, which is expected to occur in the sec
- Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During ARVO 2021https://modernod.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo-2021/2479139/Bausch + Lomb announced the presentation of new scientific data and clinical analyses, including one podium presentation and 11 poster presentations, during the virtual Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place from Ma
- Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Trial of AR-15512 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-its-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-for-the-treatment-of-patients-with-dry-eye-disease/2479134/Aerie Pharmaceuticals announced the completion of patient enrollment for COMET-1, a phase 2b clinical trial of AR-15512 (TRPM8 Agonist) ophthalmic solution for the treatment of patients with dry eye disease. The first patient to enter this randomized, double-masked, vehicle-controlled phas
- Adverum Biotechnologies Reports a Adverse Reaction of Hypotony in the INFINITY Trial Evaluating ADVM-022 in Patients With DMEhttps://modernod.com/news/adverum-biotechnologies-reports-a-adverse-reaction-of-hypotony-in-the-infinity-trial-evaluating-advm-022-in-patients-with-dme/2479135/Adverum Biotechnologies announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurr
- Heidelberg Engineering and RetInSight to Offer AI-Based OCT Fluid Quantification Solutionhttps://modernod.com/news/heidelberg-engineering-and-retinsight-to-offer-ai-based-oct-fluid-quantification-solution/2479136/Heidelberg Engineering and RetInSight announced they intend to interface the RetInSight AI-based fluid monitor application with the Heidelberg Engineering product portfolio, using cloud exchange and application marketplace technologies. RetInSight utilizes a novel, proprietary algorithm, t
- Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.https://modernod.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products – Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Dro
- Eyemate System for Remote Glaucoma Management Obtains FDA Breakthrough Device Designationhttps://modernod.com/news/eyemate-system-for-remote-glaucoma-management-obtains-fda-breakthrough-device-designation/2479126/Implandata Ophthalmic Products announced today that its Eyemate system for digitally enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the US FDA. A BDD is only assigned for breakthrough technologies that have the potential to pro